RT Journal Article
SR Electronic
T1 Genetic, structural and clinical analysis of spastic paraplegia 4
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.20.21259482
DO 10.1101/2021.07.20.21259482
A1 Varghaei, Parizad
A1 Estiar, Mehrdad A
A1 Ashtiani, Setareh
A1 Veyron, Simon
A1 Mufti, Kheireddin
A1 Leveille, Etienne
A1 Yu, Eric
A1 Spiegelman, Dan
A1 Rioux, Marie-France
A1 Yoon, Grace
A1 Tarnopolsky, Mark
A1 Boycott, Kym M.
A1 Dupre, Nicolas
A1 Suchowersky, Oksana
A1 Trempe, Jean-François
A1 Rouleau, Guy A.
A1 Gan-Or, Ziv
YR 2021
UL http://medrxiv.org/content/early/2021/07/20/2021.07.20.21259482.abstract
AB Background Spastic paraplegia type 4 (SPG4), resulting from heterozygous mutations in the SPAST gene, is the most common form among the heterogeneous group of hereditary spastic paraplegias (HSPs).Objective To study genetic and clinical characteristics of SPG4 across Canada.Methods The SPAST gene was analyzed in a total of 696 HSP patients from 431 families by either HSP-gene panel sequencing or whole exome sequencing (WES). We used Multiplex ligation-dependent probe amplification to analyze copy number variations (CNVs), and performed in silico structural analysis of selected mutations. Clinical characteristics of patients were assessed, and long-term follow-up was done to study genotype-phenotype correlations.Results We identified 157 SPG4 patients from 65 families who carried 41 different SPAST mutations, six of which are novel and six are CNVs. We report novel aspects of mutations occurring in Arg499, a case with homozygous mutation, a family with probable compound heterozygous mutations, three patients with de novo mutations, three cases with pathogenic synonymous mutation, co-occurrence of SPG4 and multiple sclerosis, and novel or rarely reported signs and symptoms seen in SPG4 patients.Conclusion Our study demonstrates that SPG4 is a heterogeneous type of HSP, with diverse genetic features and clinical manifestations. In rare cases, biallelic inheritance, de novo mutation, pathogenic synonymous mutations and CNVs should be considered.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by CIHR Emerging Team Grant, in collaboration with the Canadian Organization for Rare Disorders (CORD), grant number RN127580 — 260005, and by a CIHR Foundation grant granted to GAR. MAE is funded by the Fonds de Recherche du Québec—Santé (FRQS). GAR holds the Wilder Penfield Chair in Neurosciences. ZGO is supported by the Fonds de recherche du Québec—Santé Chercheur–Boursier award and is a William Dawson Scholar. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants have signed an informed consent form prior to enrollment, and the The McGill University Health Center (MUHC) Research Ethics Board (REB) have approved the study protocols, REB number IRB00010120.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0